JSPR241220C7500
- 0.00
- 0.000.00%
Jasper Therapeutics Newsroom
Jasper Therapeutics Initiated at Outperform by BMO Capital
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $60 to $70
Promising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in Briquilimab
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $80
JMP Securities Reiterates Market Outperform on Jasper Therapeutics, Maintains $70 Price Target
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $55 to $90
Jasper Therapeutics Analyst Ratings
Buy Rating Affirmed for Jasper Therapeutics Amidst Promising Briquilimab Clinical Data and Market Potential
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80